본문 바로가기
KERD
논문KCI 등재

Optimizing Infliximab Use in Real-World Inflammatory Bowel Disease: Insights from a Population Pharmacokinetic Model Integrating Intravenous and Subcutaneous Formulations

0

조회

0

다운로드

0

인용

0

참고문헌

참고문헌 (10)

관련 논문AI추천

Population Pharmacokinetic Model for the Use of Intravenous or Subcutaneous Infliximab in Patients with Inflammatory Bowel Disease: Real-World Data from a Prospective Cohort StudyChang Dong Kyung, Hong Sung Noh, Kim Eun Ran, Kim Minjung, Kim Myeong Gyu, Kim Seong Kyung, Kim Young-Ho, Song Joo Hye거트앤리버 소화기연관학회협의회 · Gut and Liver2025 · 제19권 제3호Lesson from Real-World Experience: Optimal Treatment with Anti-Tumor Necrosis Factor for Ulcerative ColitisChun Jaeyoung거트앤리버 소화기연관학회협의회 · Gut and Liver2021 · 제15권 제6호Assessment of Medication Adherence and Pharmacist Intervention Are Important for the Care of Patients with Inflammatory Bowel DiseaseKang Ben, Kim Eun Sil거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제5호Infliximab versus Adalimumab: Can We Choose the Right One for the Right Patients with Ulcerative Colitis?Park Sang Hyoung, Yang Suk-Kyun, Ye Byong Duk거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제1호Effectiveness of Switching to Subcutaneous Infliximab in Ulcerative Colitis Patients Experiencing Intravenous Infliximab Failure명승재, 박상형, 변정식, 양동훈, 양석균, 예병덕, 황성욱, Bae June Hwa, Baek Ji Eun, Hong Seung Wook, Park Jung-Bin거트앤리버 소화기연관학회협의회 · Gut and Liver2024 · 제18권 제4호Therapeutic Drug Monitoring of Biologics for Patients with Inflammatory Bowel Diseases: How, When, and for Whom?Wu Jia-Feng거트앤리버 소화기연관학회협의회 · Gut and Liver2022 · 제16권 제4호

이 간행물의 다른 논문 (18건)